Similar articles

• Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

  Lynch MJ. Lynch MJ. J Urol. 2005 Sep;174(3):1155; author reply 1155-6. doi: 10.1016/s0022-5347(01)68555-0. J Urol. 2005. PMID: 16094096 No abstract available.
• Substaging pathologically organ confined (pT2) prostate cancer: an exercise in futility?

  van der Kwast TH. van der Kwast TH. Eur Urol. 2006 Feb;49(2):209-11. doi: 10.1016/j.eururo.2005.12.027. Epub 2006 Jan 4. Eur Urol. 2006. PMID: 16417961 No abstract available.
• How valuable is prostate-specific antigen screening?

  Handler S. Handler S. Minn Med. 1996 Jun;79(6):2. Minn Med. 1996. PMID: 8692130 No abstract available.
• [The use of prostate specific antigen in prostate cancer--prediction for treatment failure].

  Egawa S. Egawa S. Nihon Rinsho. 2002 Dec;60 Suppl 11:100-6. Nihon Rinsho. 2002. PMID: 12599553 Review. Japanese. No abstract available.
• [PSA kinetics after total prostatectomy].

  Riedinger JM, Eche N, Fulla Y, Thuillier F. Riedinger JM, et al. Ann Biol Clin (Paris). 2009 Jan-Feb;67(1):39-46. doi: 10.1684/abc.2009.0298. Ann Biol Clin (Paris). 2009. PMID: 19189884 Review. French.